Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
1995 3
1996 1
1997 1
1998 2
1999 4
2000 2
2001 3
2002 4
2003 14
2004 15
2005 19
2006 19
2007 13
2008 21
2009 39
2010 43
2011 55
2012 61
2013 46
2014 52
2015 38
2016 37
2017 48
2018 44
2019 32
2020 35
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

568 results
Results by year
Filters applied: . Clear all
Page 1
Clofarabine.
[No authors listed] [No authors listed] 2017 Oct 17. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31643513 Free Books & Documents. Review.
Clofarabine is a purine analogue and antineoplastic agent used in the therapy of acute lymphoblastic leukemia (ALL) in children. Clofarabine is associated with frequent transient serum enzyme elevations during therapy, but they are usually asymptomatic and transient
Clofarabine is a purine analogue and antineoplastic agent used in the therapy of acute lymphoblastic leukemia (ALL) in children. C
Clofarabine in leukemia.
Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Ghanem H, et al. Expert Rev Hematol. 2010 Feb;3(1):15-22. doi: 10.1586/ehm.09.70. Expert Rev Hematol. 2010. PMID: 21082931 Review.
Clofarabine is a second-generation purine nucleoside analogue that has been synthesized to overcome the limitations and incorporate the best qualities of fludarabine and cladribine. Clofarabine acts by inhibiting ribonucleotide reductase and DNA polymerase, thereby
Clofarabine is a second-generation purine nucleoside analogue that has been synthesized to overcome the limitations and incorporate t
Clofarabine.
Pui CH, Jeha S. Pui CH, et al. Nat Rev Drug Discov. 2005 May;Suppl:S12-3. doi: 10.1038/nrd1724. Nat Rev Drug Discov. 2005. PMID: 15962525 Review.
Clofarabine (Clolar; Genzyme), a purine nucleoside antimetabolite, was granted accelerated approval by the US FDA for the treatment of paediatric patients with relapsed or refractory acute lymphoblastic leukaemia in December 2004. ...
Clofarabine (Clolar; Genzyme), a purine nucleoside antimetabolite, was granted accelerated approval by the US FDA for the treatment o
Clofarabine.
[No authors listed] [No authors listed] Drugs R D. 2004;5(4):213-7. doi: 10.2165/00126839-200405040-00005. Drugs R D. 2004. PMID: 15230627 Review.
The companies are planning to investigate the potential use of clofarabine in combination with DNA-damaging agents, because clofarabine has been shown to inhibit DNA repair and may, therefore, potentiate the effects of DNA damaging drugs. ...In addition, ILEX said i …
The companies are planning to investigate the potential use of clofarabine in combination with DNA-damaging agents, because clofar
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.
Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH. Rubnitz JE, et al. J Clin Oncol. 2019 Aug 10;37(23):2072-2081. doi: 10.1200/JCO.19.00327. Epub 2019 Jun 27. J Clin Oncol. 2019. PMID: 31246522 Free PMC article. Clinical Trial.
PURPOSE: To identify effective and less toxic therapy for children with acute myeloid leukemia, we introduced clofarabine into the first course of remission induction to reduce exposure to daunorubicin and etoposide. PATIENTS AND METHODS: From 2008 through 2017, 285 patien …
PURPOSE: To identify effective and less toxic therapy for children with acute myeloid leukemia, we introduced clofarabine into the fi …
Clofarabine-induced bluish discolouration of teeth.
Doval D, Sharma SK, Choudhary D, Kumar M, Khandelwal V. Doval D, et al. Br J Haematol. 2019 Nov;187(3):274. doi: 10.1111/bjh.16134. Epub 2019 Aug 5. Br J Haematol. 2019. PMID: 31385288 No abstract available.
Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, Ziino O, Parasole R, Luciani M, Lo Nigro L, De Rossi G, Varotto S, Bertorello N, Petruzziello F, Calvillo M, Micalizzi C. Miano M, et al. Leuk Lymphoma. 2012 Sep;53(9):1693-8. doi: 10.3109/10428194.2012.663915. Epub 2012 Mar 13. Leuk Lymphoma. 2012. PMID: 22303898 Clinical Trial.
Clofarabine is a promising new chemotherapeutic agent that is active in the treatment of pediatric acute leukemia. Forty children (16 with acute myeloid leukemia [AML], 24 with acute lymphoblastic leukemia [ALL]), aged 1-20 years (median 7.6 years) with relapsed or refract
Clofarabine is a promising new chemotherapeutic agent that is active in the treatment of pediatric acute leukemia. Forty children (16
Clofarabine Commandeers the RNR-alpha-ZRANB3 Nuclear Signaling Axis.
Long MJC, Zhao Y, Aye Y. Long MJC, et al. Cell Chem Biol. 2020 Jan 16;27(1):122-133.e5. doi: 10.1016/j.chembiol.2019.11.012. Epub 2019 Dec 10. Cell Chem Biol. 2020. PMID: 31836351 Free PMC article.
Ribonucleotide reductase (RNR) is an essential enzyme in DNA biogenesis and a target of several chemotherapeutics. Here, we investigate how anti-leukemic drugs (e.g., clofarabine [ClF]) that target one of the two subunits of RNR, RNR-alpha, affect non-canonical RNR-alpha f …
Ribonucleotide reductase (RNR) is an essential enzyme in DNA biogenesis and a target of several chemotherapeutics. Here, we investigate how …
Clofarabine for myelodysplastic syndromes.
Tiu RV, Traina F, Sekeres MA. Tiu RV, et al. Expert Opin Investig Drugs. 2011 Jul;20(7):1005-14. doi: 10.1517/13543784.2011.585967. Epub 2011 May 19. Expert Opin Investig Drugs. 2011. PMID: 21591997 Review.
Although myelosuppression is an important side effect, clofarabine is generally well tolerated in MDS. Clofarabine is currently available in an intravenous form with an oral formulation presently under investigation, either as a single agent or in combination therap …
Although myelosuppression is an important side effect, clofarabine is generally well tolerated in MDS. Clofarabine is currentl …
568 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page